Massachusetts Biomedical Initiatives (MBI) Welcomes Three Companies to the Incubator in Third Quarter of 2025

Worcester, MA (December 12, 2025) – Massachusetts Biomedical Initiatives (MBI), the longest-running non-profit life sciences incubator in the Commonwealth dedicated to creating a biomanufacturing hub in Central Massachusetts, is pleased to announce that it welcomed three companies to its incubator in the third quarter of 2025. Other third quarter updates include staff promotions and new personnel, the graduation of SpadXTech from the incubator, and incubator resident Leal Therapeutics raised a $30 million Series A funding round.

“It’s an exciting time to be in Central Massachusetts. The companies joining our incubator – and the ones graduating from it – are driving the future of the life sciences industry. Their success is a sign of the talent, innovation, and creativity that define this region. We’re honored to support them and to help build a place where innovators can plant roots and thrive,” said Jon Weaver, President and CEO of MBI.

MBI welcomed the following startups this quarter:

• Revolution Biomanufacturing is an innovative biomanufacturer focused on personalized medicine and unmet medical needs. With cutting-edge expertise in mRNA synthesis, template production, protein fermentation and purification, and lipid nanoparticle (LNP) formulation, it delivers scalable, end-to-end biomanufacturing solutions that enable faster, more efficient drug development.
• Therapeutics by Design is a biotech startup, pioneering the development of growth factor mimetics for the treatment of a broad spectrum of diseases. Therapeutics by Design’s initial focus is to use peptide mimetics for the Bone Morphogenetic Protein signaling pathway. “
• Targeted Bioscience is a biotech startup, pioneering the development of growth factor mimetics for the treatment of a broad spectrum of diseases. Therapeutics by Design’s initial focus is to use peptide mimetics for the Bone Morphogenetic Protein signaling pathway.

With the addition of these innovative new companies, MBI is at 90% capacity, demonstrating the growing demand for startup and lab space in the Central Massachusetts region. The unique StartUp & ScaleUp model at MBI bridges the gap between incubator and commercial market spaces for early-stage, growing companies. The StartUp space offers small, private labs for founders to launch companies. As they grow, companies can move into the ScaleUp space which offers larger accommodations and private office suites intended for scaling teams and technology. MBI’s Pilot Biomanufacturing Center provides space designed to support early-stage clinical manufacturing. This model allows companies to move into larger, more appropriate spaces as they scale, freeing up space in the incubator for new, promising companies to enter the pipeline.

Graduates:

• SpadXTech is dedicated to employing the power of microbes and synthetic biology to produce high performance, circular materials to significantly reduce pollution and greenhouse gas emissions, graduated from the MBI incubator.
• Loop CO2, Inc. is a green chemistry research and development startup specialized in developing a new class of polyester materials in the form of pellets for manufacturing consumer products from a CO2-derived monomer feedstock.

Both SpadXTech and Loop CO2 are now located in Marlborough.

Additional highlights and updates from MBI and our companies:

• Worcester was ranked amongst the top 10 mid-sized metros for STEM jobs, according to a new analysis from CoworkingCafe.
• Secretary of Economic Development Eric Paley visited MBI and met with President and CEO Jon Weaver for a tour of the incubator facility and a conversation about the growing biomanufacturing industry in Central MA. (photos available upon request)
• Lean Therapeutics closed a $30M Series A round. Leal Therapeutics is advancing groundbreaking work developing new treatments for CNS and neurodegenerative disorders
• SauveBio moved into a larger lab space at MBI, allowing it to scale operations, support more clients, and accelerate discovery.
• Recent graduate SpadXTech was awarded a $200K Technology Enhancement for Commercial Partnerships (TECP) grant from the National Science Foundation (NSF)
• Enamel Pure received an investment from the Baylor Angel Network. Enamel Pure is leveraging novel laser and imaging technology to advance the standard of care in preventive dentistry. The company has developed an FDA approved device that implements CO2 laser technology to make enamel more resistant to acid and prevent cavities and erosion.
• Codomax received a spotlight from Genetic Engineering & Biotechnology News. Codomax is pioneering a tRNA-focused strategy to address a critical roadblock in biomanufacturing scale-up and has made a major leap for harder-to-express proteins.
• Jura Bio announced VISTA, its new platform that creates a powerful, continuous feedback loop for AI-driven drug design.

###

About Massachusetts Biomedical Initiatives

MBI is a non-profit focused on building the Central Massachusetts bio-cluster. MBI’s mission is to be a partner for fostering innovation in the life sciences and achieves that goal through its small business incubator system, workforce development efforts, and regional economic development initiatives. It is estimated that since 2000, MBI has assisted over 197 companies that have created over 1,800 jobs resulting in a $2 billion economic impact.

Media Contact:

Alicia Curran, acurran@aliciacurrancommunications.com, cell: 407-797-2076